【摘要】 目的评价丁苯酞序贯疗法治疗急性脑梗死的疗效及安全性。方法计算机检索中国期刊全文数据库(CNKI)、万方数据库(WanFang Data)、维普中文科技期刊数据库(cqVIP.com)、中国生物医学文献服务系统(SinoMed)、Cochrane Library、PubMed及Web of Science,检索有关丁苯酞序贯疗法治疗急性脑梗死的随机对照试验(RCT),检索时间为2015年5月1日至2020年7月1日。由2名评价员独立筛选文献、提取相关资料并评价纳入研究的偏倚风险后,通过Revman 5.3软件进行Meta分析。结果最终纳入12项RCT,共1307例患者,其中丁苯酞序贯治疗试验组655例,对照组(常规治疗或常规治疗+丁苯酞注射液或常规治疗+依达拉奉注射液)652例。Meta分析结果显示,与对照组相比,丁苯酞序贯治疗组在美国国立卫生研究院卒中量表评分(MD=-3.57,95%CI:-4.56～-2.58,P<0.001)、Barthel指数(MD=10.73,95%CI:6.14～15.31,P<0.001)和治疗总有效率(RR=1.19,95%CI:1.09～1.31,P<0.001)方面,差异均有统计学意义。2组治疗期间发生不良反应较少,主要为转氨酶升高,但均较轻微。结论丁苯酞序贯疗法治疗急性脑梗死具有较好疗效及安全性。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of butylphthalide sequential therapy in the treatment of acute cerebral infarction. Methods Internet search in China National Knowledge Infrastructure(CNKI), Wanfang Database(WanFang), VIP Database(VIP), China Biomedical Document Service System(SinoMed), Cochrane Library, PubMed and Web of Science. We collected relevant documents of randomized controlled trials of phthalide sequential therapy in the treatment of acute cerebral infarction. The publish time was from May 1, 2015 to July 1, 2020. After two reviewers independently screened the literature, extracted relevant data, and evaluated the risk of bias in the included studies, metaanalysis was performed through Revman 5.3 software. Results Twelve RCTs were finally included, with a total of 1307 patients, including 655 cases of the butylphthalide sequential treatment group, and 652 cases of the control group(conventional treatment or conventional treatment+butylphthalide injection or conventional treatment+edaravone injection). Meta-analysis results showed that there were statistically significant differences between the butylphthalide sequential treatment group and the control group in the NIHSS score(MD=-3.57,95%CI:-4.56～-2.58, P<0.001), Barthel index(MD=10.73, 95%CI: 6.14-15.31, P<0.001) and the total efficacy of treatment(RR=1.19, 95%CI: 1.09-1.31, P<0.001). During treatment, the two groups had fewer adverse reactions, mainly elevated transaminases, but they were all mild. Conclusion Butylphthalide sequential therapy has good efficacy and safety in the treatment of acute cerebral infarction.更多还原